Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects (EMPA)

What is the purpose of this trial?

The investigators propose a small pilot proof of concept study to not only prove the existence of, but also probe the mechanisms underlying cardio-renal effects of empagliflozin in patients with heart failure. The investigators propose a 50 patient randomized, double-blind, placebo-controlled crossover study with patients with stable HF, type II diabetes and an eGFR >45ml/min/1.73 m2 who are chronically receiving loop diuretics.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Boehringer Ingelheim Pharmaceuticals, Inc.

Dates: 04/19/2017 - 10/31/2018

Last Updated: 06/15/2017

Study HIC#: 2000020019

Get Involved

For more information about this study, contact:
Amanda Kate Hittinger
203-859-8788
amanda.hittinger@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image